Ophthalmology
My top five: Emerging alternatives to manage and treat nAMD
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...
My top five: Innovative approaches to dry AMD
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
Update on emerging therapies for age-related macular degeneration
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
Simulating the visual impairment symptoms of age-related macular degeneration in virtual reality
A new virtual reality application visually simulates age-related macular degeneration and demonstrates its progression over time including some Charles Bonnet syndrome hallucinations. Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with the prevalence of...
Post-Brexit deal welcomed but leaves future relationship with EU far from settled
Rod McNeil breaks down the impact of the Brexit deal on healthcare in the UK, including medicines regulation, research funding, sharing of information and the ability to work abroad. A disorderly no-deal exit from the European Union (EU) was averted...
Decoding the red eye
Red eye, or hyperaemia, is one of the most common presentations to primary care [1] and the emergency department [2]. However, despite this the underlying cause is often misdiagnosed which can lead to severe, sight-threatening conditions being missed [1]. Thorough...
Eyecare education in times of COVID-19
A collaboration between the German Committee for the Prevention of Blindness (DKVB), Rukwa regional government in Tanzania and the University of St Andrews Global Health Team successfully delivered a hybrid teaching programme for ophthalmic nurses in Sumbawanga, south west Tanzania,...
Educational concerns and anxiety levels amongst ophthalmology trainees during the COVID-19 pandemic
How concerned are ophthalmology trainees about the present impact and the future consequences of suspended ophthalmic training programmes? Researchers in the West of Scotland investigate. Anxiety, stress and the longer-term stress reaction of burnout often go unrecognised, yet are known...
The Re-humanising Revolution: Breaking the conspiracy of silence
Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...
Corporate M&A pace gathers momentum
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
Quality matters in the management of serious eye disorders
The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...
Assessing everyday visual function in dry AMD – what matters to the person?
Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...
